Next Article in Journal
Zebrafish, an In Vivo Platform to Screen Drugs and Proteins for Biomedical Use
Previous Article in Journal
State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis
Previous Article in Special Issue
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
Article

Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices

1
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium
2
Pharmacy Department, Faculty of Pharmaceutical Sciences, UZ Gent, 9000 Gent, Belgium
3
Hospital Pharmacy, Erasmus University Medical Center, 3015 CN Rotterdam, The Netherlands
*
Author to whom correspondence should be addressed.
Academic Editor: Jean Jacques Vanden Eynde
Pharmaceuticals 2021, 14(6), 499; https://doi.org/10.3390/ph14060499
Received: 19 March 2021 / Revised: 12 May 2021 / Accepted: 14 May 2021 / Published: 24 May 2021
(This article belongs to the Special Issue Biosimilars in Europe)
Background: In Europe, off-patent biologicals and biosimilars are largely procured by means of tender procedures. The organization and design of tenders may play a key role in the evolving biosimilar market, and currently, it is not fully elucidated how tenders for off-patent biologicals and biosimilars are designed and if approaches are aligned with sustaining market competition and societal savings for healthcare systems over the long term. This study aims to (i) explore the design and implementation of tender procedures for off-patent biologicals and biosimilars in Europe, (ii) identify learnings for sustainable tender approaches from purchasers and suppliers, and (iii) formulate recommendations in support of competitive and sustainable tender practices in the off-patent biologicals market. Methods: A mixed methods design was applied. A quantitative web-survey was conducted with hospital pharmacists and purchasers (N = 60, of which 47 completed the survey in full), and qualitative expert-interviews with purchasers and suppliers (N = 28) were carried out. Results: The web survey results showed that the organization and design of tenders for off-patent biologicals and biosimilars, and the experience of hospital pharmacists and purchasers with this, considerably varies on several elements across European countries. From the qualitative interviews, signals emerged across the board that some of the current tender approaches might negatively affect market dynamics for off-patent biologicals and biosimilars. The focus on generating short-term savings and existence of originator favouring tender practices were identified as elements that may limit timely competition from and market opportunity for biosimilar suppliers. The need to optimize tender processes, considering a more long-term strategic and sustainable view, was expressed. In addition, challenges appear to exist with differentiating between products beyond price, showing the need and opportunity to guide stakeholders with the (appropriate) inclusion of award criteria beyond price. Due to the variety in tender organization in Europe, a ‘one size fits all’ tendering framework is not possible. However, on an overarching level, it was argued that tender procedures must aim to (i) ensure market plurality and (ii) include award criteria beyond price (warranted that criteria are objectively and transparently defined, scored and competitively rewarded). Depending on the market (maturity), additional actions may be needed. Conclusions: Findings suggest the need to adjust tender procedures for off-patent biologicals and biosimilars, considering a more long-term strategic and market sustainable view. Five main avenues for optimization were identified: (i) safeguarding a transparent, equal opportunity setting for all suppliers with an appropriate use of award criteria; (ii) fostering a timely opening of tender procedures, ensuring on-set competition; (iii) ensuring and stimulating adherence to laws on public procurement; (iv) securing an efficient process, improving plannability and ensuring timely product supply and (v) safeguarding long-term sustainable competition by stimulating market plurality. View Full-Text
Keywords: tender; procurement; off-patent; biological; biosimilar; award criteria; switching; interchangeability; sustainability; competition tender; procurement; off-patent; biological; biosimilar; award criteria; switching; interchangeability; sustainability; competition
Show Figures

Graphical abstract

MDPI and ACS Style

Barbier, L.; Simoens, S.; Soontjens, C.; Claus, B.; Vulto, A.G.; Huys, I. Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices. Pharmaceuticals 2021, 14, 499. https://doi.org/10.3390/ph14060499

AMA Style

Barbier L, Simoens S, Soontjens C, Claus B, Vulto AG, Huys I. Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices. Pharmaceuticals. 2021; 14(6):499. https://doi.org/10.3390/ph14060499

Chicago/Turabian Style

Barbier, Liese, Steven Simoens, Caroline Soontjens, Barbara Claus, Arnold G. Vulto, and Isabelle Huys. 2021. "Off-Patent Biologicals and Biosimilars Tendering in Europe—A Proposal towards More Sustainable Practices" Pharmaceuticals 14, no. 6: 499. https://doi.org/10.3390/ph14060499

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop